Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46


Addressing research priorities for prevention of HIV infection in the United States.

Vermund SH, Hodder SL, Justman JE, Koblin BA, Mastro TD, Mayer KH, Wheeler DP, El-Sadr WM.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S149-55. doi: 10.1086/651485. Review.


HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.

Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):65-72. doi: 10.1097/QAI.0b013e3181d916db.


Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users.

Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, Hogg RS, Montaner JS, Wood E.

Addiction. 2010 May;105(5):907-13. doi: 10.1111/j.1360-0443.2010.02905.x. Epub 2010 Mar 10.


The Chinese government's response to drug use and HIV/AIDS: a review of policies and programs.

Li J, Ha TH, Zhang C, Liu H.

Harm Reduct J. 2010 Mar 5;7:4. doi: 10.1186/1477-7517-7-4.


HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.

Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA; 2009 Reference Group to the UN on HIV and Injecting Drug Use.

Lancet. 2010 Mar 20;375(9719):1014-28. doi: 10.1016/S0140-6736(10)60232-2. Epub 2010 Feb 26. Review.


Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users.

Meader N, Li R, Des Jarlais DC, Pilling S.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007192. doi: 10.1002/14651858.CD007192.pub2. Review.


Reducing sex under the influence of drugs or alcohol for patients in substance abuse treatment.

Calsyn DA, Crits-Christoph P, Hatch-Maillette MA, Doyle SR, Song YS, Coyer S, Pelta S.

Addiction. 2010 Jan;105(1):100-8. doi: 10.1111/j.1360-0443.2009.02812.x.


Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.

Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B.

Clin Infect Dis. 2009 Nov 1;49(9):1433-40. doi: 10.1086/630209.


Social and structural determinants of HAART access and adherence among injection drug users.

Kr├╝si A, Wood E, Montaner J, Kerr T.

Int J Drug Policy. 2010 Jan;21(1):4-9. doi: 10.1016/j.drugpo.2009.08.003. Epub 2009 Sep 10.


Systematic review of HIV and HCV infection among drug users in China.

Bao YP, Liu ZM.

Int J STD AIDS. 2009 Jun;20(6):399-405. doi: 10.1258/ijsa.2008.008362. Review.


HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Chander G, Himelhoch S, Fleishman JA, Hellinger J, Gaist P, Moore RD, Gebo KA.

AIDS Care. 2009 May;21(5):655-63. doi: 10.1080/09540120802459762.


Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men.

Calsyn DA, Hatch-Maillette M, Tross S, Doyle SR, Crits-Christoph P, Song YS, Harrer JM, Lalos G, Berns SB.

J Subst Abuse Treat. 2009 Sep;37(2):138-50. doi: 10.1016/j.jsat.2008.11.008. Epub 2009 Jan 15.


Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV.

Barnett PG, Sorensen JL, Wong W, Haug NA, Hall SM.

Drug Alcohol Depend. 2009 Feb 1;100(1-2):115-21. doi: 10.1016/j.drugalcdep.2008.09.017. Epub 2008 Dec 3.


The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group.

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4.


Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial.

Tross S, Campbell AN, Cohen LR, Calsyn D, Pavlicova M, Miele GM, Hu MC, Haynes L, Nugent N, Gan W, Hatch-Maillette M, Mandler R, McLaughlin P, El-Bassel N, Crits-Christoph P, Nunes EV.

J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):581-9. doi: 10.1097/QAI.0b013e31817efb6e.


Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Schottenfeld RS, Chawarski MC, Mazlan M.

Lancet. 2008 Jun 28;371(9631):2192-200. doi: 10.1016/S0140-6736(08)60954-X.


Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, Montaner JS.

J Infect Dis. 2008 Jul 1;198(1):59-67. doi: 10.1086/588673.


Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.

Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA.

J Subst Abuse Treat. 2008 Jul;35(1):87-92. Epub 2007 Oct 15.


Impact of methadone on drug use and risky sex in China.

Qian HZ, Hao C, Ruan Y, Cassell HM, Chen K, Qin G, Yin L, Schumacher JE, Liang S, Shao Y.

J Subst Abuse Treat. 2008 Jun;34(4):391-7. Epub 2007 Sep 14.


Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).

Spire B, Lucas GM, Carrieri MP.

Int J Drug Policy. 2007 Aug;18(4):262-70. Epub 2007 Jan 26. Review.


Supplemental Content

Support Center